TAPI and Antheia have announced a new strategic partnership designed to support the commercialization of Antheia’s biosynthetic key starting materials (KSMs) and active pharmaceutical ingredients (APIs). Antheia will leverage TAPI’s next-generation fermentation capabilities and manufacturing facilities in Europe to scale its pipeline and accelerate time to market for future product launches.
This collaboration combines Antheia’s innovative biosynthesis platform with TAPI’s advanced bioprocessing and manufacturing capabilities. The existing infrastructure, capacity, and quality management systems TAPI provides are well suited for Antheia’s processes, enabling efficient, reliable, and high-quality production at commercial scale. The partnership is positioned to support multiple products in Antheia’s pipeline and strengthen the long-term commercialization strategy.
With nearly a century of API manufacturing experience, TAPI offers the expertise and state-of-the-art infrastructure needed to support Antheia’s mission to transform pharmaceutical supply chains and advance essential medicines.
This collaboration reflects TAPI’s role in bringing scientific innovation and manufacturing excellence together. Through a flexible tech-transfer model and a collaborative, problem-solving approach, TAPI will support Antheia’s biosynthetic platform with advanced fermentation and enzymatic capabilities that help make these complex processes commercially viable.
To read the full announcement, click here: Antheia and TAPI Partner to Advance Global Commercialization Strategy for Critical Pharmaceutical Ingredients
